2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2925 Hematocrit to viscosity ratio measured under hypoxia is associated with acute chest syndrome burden in sickle cell disease

Mary C Aliche, BS, Neha H Suresh, BS2, Justin J Yoo, M.D.3, Ashwin Prahladbhai Patel, MBBS, PhD4, Vivien A Sheehan, MD,PhD5
1 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, United States
2 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Hematology and Medical Oncology, Atlanta, Georgia, United States
4 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, United States
5 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, United States

Introduction: 

Sickle cell disease is an inherited blood disorder driven by the polymerization of sickle hemoglobin (HbS). Under hypoxic conditions, HbS forms long, rigid polymers within red blood cells (RBCs), which decrease RBC deformability and increase whole blood viscosity (WBV). These rheological changes impair blood flow and contribute to vaso-occulsive events (VOE), acute chest syndrome (ACS), and other disease-related hospitalizations.  

The hematocrit to viscosity ratio (HVR), calculated as hematocrit divided by WBV, reports oxygen carrying capacity, which is lower in HbSS compared to HbAA, consistent with reduced oxygen transport effectiveness. Previous studies found that higher WBV measured under normoxia was associated with a higher incidence of vaso-occlusive complications in SCD (Nebor et al. 2011; Lamarre et al. 2012). However, normoxic measurements do not capture the rheological consequences of HbS polymerization under hypoxia. HVR has not been measured under hypoxic WBV and correlation with rates of ACS has not been assessed. We developed a chemical hypoxia-based viscosity assay to quantify the HVR under hypoxia and evaluated the associations of hypoxic HVR and the change from normoxia to hypoxia with rates of ACS in SCD. We hypothesized that a lower HVR under hypoxia compared to HVR under normoxia would be associated with higher rates of ACS, and that HVR under hypoxia would be a superior biomarker for acute event risk than normoxic HVR alone.  

Methods: 

Peripheral blood samples collected in EDTA from 50 individuals with HbSS were evaluated using our previously developed hypoxic WBV assay. WBV was measured at shear rates 45 s-1 and 225 s-1 using a cone and plate viscometer (Brookfield) before and after chemical hypoxia with 50 mg of sodium metabisulfite (MBS). HVR was calculated at each shear rate by dividing the sample hematocrit by WBV.  

Clinical data was retrospectively abstracted from electronic medical records (EMR) for 2 years preceding sample collection to determine annualized ACS rates. Paired normoxic and hypoxic HVR measurements were compared using a Wilcoxon matched-pairs signed rank test. Associations between HVR and ACS were evaluated using Spearman correlation. Negative binomial regression was used to evaluate ACS counts, and patients with and without prior ACS were compared using a Mann-Whitney test. A two-sided p<0.05 was considered significant.  

Results: 

Paired HVR measurements were available for 47 individuals at 45 s-1 and 225 s-1. Hypoxia significantly reduced HVR at both shear rates. Median HVR decreased from 7.72 under normoxia to 3.22 under hypoxia at 45 s-1 (p<0.0001) and from 8.08 to 4.42 at 225 s-1 (p<0.0001). Lower hypoxic HVR at 225 s-1 was associated with a higher annualized ACS rate during the two years preceding sample collection (Spearman rs=−0.396, p=0.0085), whereas normoxic HVR was not associated (rs=−0.200, p=0.198). In negative binomial regression, each one-unit increase in hypoxic HVR225 was associated with a 73% lower ACS incidence rate (IRR=0.27, 95% Cl 0.10-0.71, p=0.0078). Individuals with prior ACS also had a lower median hypoxic HVR than those without prior ACS (4.20 vs 4.61, p=0.0166).  

Discussion: 

An association between HVR and ACS was observed only when HVR was measured under hypoxia. Lower HVR under hypoxia compared to normoxia at 225 s-1 was consistently associated with greater historical ACS burden across correlation, count-based, and categorical analyses, whereas normoxic HVR at the same shear rate showed no significant association with ACS rate. This contrast demonstrates a limitation of conventional normoxic rheological assessment. Clinically relevant reduced oxygen carrying capacity may remain undetected when blood is evaluated under normoxia. By capturing the rheological consequences of HbS polymerization, hypoxic HVR provides ACS burden rates that are not apparent from normoxic measurements. Prospective validation in a larger cohort is needed to establish thresholds for pathologic HVR under hypoxia and predictions for future ACS. As disease-modifying and potentially curative therapies continue to advance, hypoxic HVR may provide a clinically relevant approach for identifying patients with disproportionate rheological impairment and ACS risk.  

Mary C Aliche, BS: No relevant conflicts of interest to declare.